Sugi Predict

Sugi Predict / Compounds / SCHEMBL4858749

SCHEMBL4858749

SCHEMBL4858749

O=C(CCl)Nc1ccc2ncccc2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 7/20 0.70
▸ POLB P06746 2/20 0.70
▸ MEN1 O00255 1/20 0.70
▸ MAPT P10636 1/20 0.70
▸ KMT2A Q03164 1/20 0.70
▸ ALDH1A1 P00352 4/20 0.66
▸ CYP3A4 P08684 2/20 0.66
▸ CYP1A2 P05177 1/20 0.66
▸ TSHR P16473 1/20 0.66
▸ HSD17B10 Q99714 1/20 0.66
▸ PABPC1 P11940 1/20 0.62
▸ NOTUM Q6P988 2/20 0.62
▸ HDAC6 Q9UBN7 2/20 0.61
▸ HDAC1 Q13547 2/20 0.61
▸ HDAC3 O15379 1/20 0.61
▸ HDAC4 P56524 1/20 0.61
▸ HDAC7 Q8WUI4 1/20 0.61
▸ HDAC2 Q92769 1/20 0.61
▸ HDAC10 Q969S8 1/20 0.61
▸ HDAC11 Q96DB2 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5142389 0.89 NPC1 (0.77) NPC1POLBMEN1MAPTKMT2A
SCHEMBL29944526 0.89 NPC1 (0.77) NPC1POLBMEN1MAPTKMT2A
SCHEMBL29728217 0.89 NPC1 (0.67) NPC1POLBMEN1MAPTKMT2A
SCHEMBL28787618 0.89 NPC1 (0.67) NPC1POLBMEN1MAPTKMT2A
SCHEMBL4855527 0.88 P2RY14 (0.62) NPC1POLBMEN1MAPTKMT2A
SCHEMBL29728194 0.86 HDAC1 (0.69) NPC1POLBMEN1MAPTKMT2A
SCHEMBL2638443 0.85 HDAC6 (0.72) NPC1POLBMEN1MAPTKMT2A
SCHEMBL21296585 0.85 NPC1 (0.70) NPC1POLBMEN1MAPTKMT2A
SCHEMBL8402849 0.85 NPC1 (0.70) NPC1POLBMEN1MAPTKMT2A
SCHEMBL2638441 0.85 NPC1 (0.70) NPC1POLBMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025229046-A1 SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME MOLIUS SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) 2025-11-06 — — WO disclosed
EP-4644375-A1 SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME Molius Saglik Teknolojileri Anonim Sirketi (TR) 2025-11-05 — — EP disclosed
CN-114436978-B Antifungal compound and application thereof 中国人民解放军海军军医大学 2024-06-18 — — CN disclosed
US-20240018135-A1 COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF MEDIFRON DBT INC. (KR) 2024-01-18 — — US disclosed
US-20240018135-A1 COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF MEDIFRON DBT INC. (KR) 2024-01-18 — — US disclosed
US-20240018135-A1 COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF MEDIFRON DBT INC. (KR) 2024-01-18 — — US disclosed
EP-4249475-A1 COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLCNACASE AND USE THEREOF MEDIFRON DBT INC. (KR) 2023-09-27 — — EP disclosed
CN-116438167-A Compounds having O-GlcNAc enzyme inhibitory activity and uses thereof 美迪福伦DBT有限公司 2023-07-14 — — CN disclosed
CN-109265451-B Butyrylcholinesterase selective inhibitor and preparation method and application thereof 中国药科大学 2022-07-15 — — CN disclosed
WO-2022108377-A1 COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLCNACASE AND USE THEREOF (주) 메디프론디비티 2022-05-27 — — WO disclosed
US-7407960-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2008-08-05 — — US disclosed
EP-1806346-A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors CV THERAPEUTICS, INC. (US) 2007-07-11 — — EP disclosed
EP-1567525-B1 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS INC (US) 2007-06-27 — — EP disclosed
US-20070004751-A1 Substituted heterocyclic compounds ELZEIN ELFATIH 2007-01-04 — — US disclosed
US-7125876-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2006-10-24 — — US disclosed
US-6995143-B2 Macrolides with antibacterial activity BASILEA PHARMACEUTICA AG (CH) 2006-02-07 — — US disclosed
EP-1478653-A1 MACROLIDES WITH ANTIBACTERIAL ACTIVITY Basilea Pharmaceutica AG (CH) 2004-11-24 — — EP disclosed
US-20040152890-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2004-08-05 — — US disclosed
US-20030212011-A1 Macrolides with antibacterial activity BASILEA PHARMACEUTICA AG (CH) 2003-11-13 — — US disclosed
WO-2003072588-A1 MACROLIDES WITH ANTIBACTERIAL ACTIVITY BASILEA PHARMACEUTICA AG (CH) 2003-09-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212011-A1 Macrolides with antibacterial activity MRPL21, RPS21, MRPS18A NPC1 133/4885POLB 3397/4885MEN1 1793/4885
US-20040152890-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A NPC1 2524/4885POLB 2675/4885MEN1 3200/4885
US-20240018135-A1 COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF OGA, OGT, ENGASE NPC1 3307/4885POLB 3871/4885MEN1 2839/4885
US-20070004751-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A NPC1 2349/4885POLB 2485/4885MEN1 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.